Five-weekly S-1 plus cisplatin therapy combined with trastuzumab therapy in HER2-positive gastric cancer

a phase II trial and biomarker study (WJOG7212G)

Yuji Miura, Yasutaka Sukawa, Shuichi Hironaka, Misuzu Mori, Kazuhiro Nishikawa, Shinya Tokunaga, Hiroyuki Okuda, Takeshi Sakamoto, Keisei Taku, Kazuo Nishikawa, Toshikazu Moriwaki, Yuji Negoro, Yutaka Kimura, Keita Uchino, Katsunori Shinozaki, Hiroharu Shinozaki, Nobuyuki Musha, Hirotsugu Yoshiyama, Takashi Tsuda, Yoshinori Miyata & 9 others Naotoshi Sugimoto, Tsuyoshi Shirakawa, Miki Ito, Kimio Yonesaka, Kenichi Yoshimura, Narikazu Boku, Katsuhiko Nosho, Toshimi Takano, Ichinosuke Hyodo

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Background: Five-weekly S-1 plus cisplatin (SP) therapy is the standard care for advanced gastric or esophagogastric junction cancer (GC/EGJC) in East Asia. However, its efficacy and safety when combined with trastuzumab therapy for human epidermal growth factor receptor 2 (HER2)-positive advanced GC/EGJC remains unclear. Methods: Patients received 5-weekly SP therapy (S-1 at 40–60 mg twice daily for 21 days plus cisplatin at 60 mg/m2 on day 8, every 5 weeks) plus trastuzumab therapy (first dose of 8 mg/kg, then 6 mg/kg every 3 weeks). The primary end point was the response rate, and the secondary end points included progression-free survival, overall survival, safety, and serum biomarker levels. Results: Forty-four patients were enrolled. The response rate, progression-free survival, and overall survival were 61% (95% confidence interval 46–76%), 5.9 months, and 16.5 months respectively. The commonest grade 3 or grade 4 adverse events were neutropenia (30%) and anorexia (25%). A significantly higher response rate (92% vs 43%; P = 0.008) and longer progression-free survival (median 14.5 months vs 4.2 months; P = 0.028) were observed in patients with high (n = 14) compared with low (n = 17) pretreatment serum neuregulin 1 levels. Conclusions: Five-weekly SP therapy combined with trastuzumab therapy showed a good antitumor response and acceptable toxicity in HER2-positive advanced GC/EGJC. Serum neuregulin 1 might be associated with the efficacy of this treatment regimen.

Original languageEnglish
Pages (from-to)1-12
Number of pages12
JournalGastric Cancer
DOIs
Publication statusAccepted/In press - 2017 May 11

Fingerprint

Cisplatin
Stomach Neoplasms
Biomarkers
Esophagogastric Junction
Neuregulin-1
Disease-Free Survival
Stomach
Therapeutics
Serum
Safety
Neoplasms
Survival
Far East
Anorexia
Neutropenia
human ERBB2 protein
Trastuzumab
Confidence Intervals

Keywords

  • First-line chemotherapy
  • Gastric adenocarcinoma
  • Neuregulin 1
  • S-1
  • Trastuzumab

ASJC Scopus subject areas

  • Oncology
  • Gastroenterology
  • Cancer Research

Cite this

Five-weekly S-1 plus cisplatin therapy combined with trastuzumab therapy in HER2-positive gastric cancer : a phase II trial and biomarker study (WJOG7212G). / Miura, Yuji; Sukawa, Yasutaka; Hironaka, Shuichi; Mori, Misuzu; Nishikawa, Kazuhiro; Tokunaga, Shinya; Okuda, Hiroyuki; Sakamoto, Takeshi; Taku, Keisei; Nishikawa, Kazuo; Moriwaki, Toshikazu; Negoro, Yuji; Kimura, Yutaka; Uchino, Keita; Shinozaki, Katsunori; Shinozaki, Hiroharu; Musha, Nobuyuki; Yoshiyama, Hirotsugu; Tsuda, Takashi; Miyata, Yoshinori; Sugimoto, Naotoshi; Shirakawa, Tsuyoshi; Ito, Miki; Yonesaka, Kimio; Yoshimura, Kenichi; Boku, Narikazu; Nosho, Katsuhiko; Takano, Toshimi; Hyodo, Ichinosuke.

In: Gastric Cancer, 11.05.2017, p. 1-12.

Research output: Contribution to journalArticle

Miura, Y, Sukawa, Y, Hironaka, S, Mori, M, Nishikawa, K, Tokunaga, S, Okuda, H, Sakamoto, T, Taku, K, Nishikawa, K, Moriwaki, T, Negoro, Y, Kimura, Y, Uchino, K, Shinozaki, K, Shinozaki, H, Musha, N, Yoshiyama, H, Tsuda, T, Miyata, Y, Sugimoto, N, Shirakawa, T, Ito, M, Yonesaka, K, Yoshimura, K, Boku, N, Nosho, K, Takano, T & Hyodo, I 2017, 'Five-weekly S-1 plus cisplatin therapy combined with trastuzumab therapy in HER2-positive gastric cancer: a phase II trial and biomarker study (WJOG7212G)', Gastric Cancer, pp. 1-12. https://doi.org/10.1007/s10120-017-0725-6
Miura, Yuji ; Sukawa, Yasutaka ; Hironaka, Shuichi ; Mori, Misuzu ; Nishikawa, Kazuhiro ; Tokunaga, Shinya ; Okuda, Hiroyuki ; Sakamoto, Takeshi ; Taku, Keisei ; Nishikawa, Kazuo ; Moriwaki, Toshikazu ; Negoro, Yuji ; Kimura, Yutaka ; Uchino, Keita ; Shinozaki, Katsunori ; Shinozaki, Hiroharu ; Musha, Nobuyuki ; Yoshiyama, Hirotsugu ; Tsuda, Takashi ; Miyata, Yoshinori ; Sugimoto, Naotoshi ; Shirakawa, Tsuyoshi ; Ito, Miki ; Yonesaka, Kimio ; Yoshimura, Kenichi ; Boku, Narikazu ; Nosho, Katsuhiko ; Takano, Toshimi ; Hyodo, Ichinosuke. / Five-weekly S-1 plus cisplatin therapy combined with trastuzumab therapy in HER2-positive gastric cancer : a phase II trial and biomarker study (WJOG7212G). In: Gastric Cancer. 2017 ; pp. 1-12.
@article{263b07780190488b82dcf85bd0ed6a72,
title = "Five-weekly S-1 plus cisplatin therapy combined with trastuzumab therapy in HER2-positive gastric cancer: a phase II trial and biomarker study (WJOG7212G)",
abstract = "Background: Five-weekly S-1 plus cisplatin (SP) therapy is the standard care for advanced gastric or esophagogastric junction cancer (GC/EGJC) in East Asia. However, its efficacy and safety when combined with trastuzumab therapy for human epidermal growth factor receptor 2 (HER2)-positive advanced GC/EGJC remains unclear. Methods: Patients received 5-weekly SP therapy (S-1 at 40–60 mg twice daily for 21 days plus cisplatin at 60 mg/m2 on day 8, every 5 weeks) plus trastuzumab therapy (first dose of 8 mg/kg, then 6 mg/kg every 3 weeks). The primary end point was the response rate, and the secondary end points included progression-free survival, overall survival, safety, and serum biomarker levels. Results: Forty-four patients were enrolled. The response rate, progression-free survival, and overall survival were 61{\%} (95{\%} confidence interval 46–76{\%}), 5.9 months, and 16.5 months respectively. The commonest grade 3 or grade 4 adverse events were neutropenia (30{\%}) and anorexia (25{\%}). A significantly higher response rate (92{\%} vs 43{\%}; P = 0.008) and longer progression-free survival (median 14.5 months vs 4.2 months; P = 0.028) were observed in patients with high (n = 14) compared with low (n = 17) pretreatment serum neuregulin 1 levels. Conclusions: Five-weekly SP therapy combined with trastuzumab therapy showed a good antitumor response and acceptable toxicity in HER2-positive advanced GC/EGJC. Serum neuregulin 1 might be associated with the efficacy of this treatment regimen.",
keywords = "First-line chemotherapy, Gastric adenocarcinoma, Neuregulin 1, S-1, Trastuzumab",
author = "Yuji Miura and Yasutaka Sukawa and Shuichi Hironaka and Misuzu Mori and Kazuhiro Nishikawa and Shinya Tokunaga and Hiroyuki Okuda and Takeshi Sakamoto and Keisei Taku and Kazuo Nishikawa and Toshikazu Moriwaki and Yuji Negoro and Yutaka Kimura and Keita Uchino and Katsunori Shinozaki and Hiroharu Shinozaki and Nobuyuki Musha and Hirotsugu Yoshiyama and Takashi Tsuda and Yoshinori Miyata and Naotoshi Sugimoto and Tsuyoshi Shirakawa and Miki Ito and Kimio Yonesaka and Kenichi Yoshimura and Narikazu Boku and Katsuhiko Nosho and Toshimi Takano and Ichinosuke Hyodo",
year = "2017",
month = "5",
day = "11",
doi = "10.1007/s10120-017-0725-6",
language = "English",
pages = "1--12",
journal = "Gastric Cancer",
issn = "1436-3291",
publisher = "Springer Japan",

}

TY - JOUR

T1 - Five-weekly S-1 plus cisplatin therapy combined with trastuzumab therapy in HER2-positive gastric cancer

T2 - a phase II trial and biomarker study (WJOG7212G)

AU - Miura, Yuji

AU - Sukawa, Yasutaka

AU - Hironaka, Shuichi

AU - Mori, Misuzu

AU - Nishikawa, Kazuhiro

AU - Tokunaga, Shinya

AU - Okuda, Hiroyuki

AU - Sakamoto, Takeshi

AU - Taku, Keisei

AU - Nishikawa, Kazuo

AU - Moriwaki, Toshikazu

AU - Negoro, Yuji

AU - Kimura, Yutaka

AU - Uchino, Keita

AU - Shinozaki, Katsunori

AU - Shinozaki, Hiroharu

AU - Musha, Nobuyuki

AU - Yoshiyama, Hirotsugu

AU - Tsuda, Takashi

AU - Miyata, Yoshinori

AU - Sugimoto, Naotoshi

AU - Shirakawa, Tsuyoshi

AU - Ito, Miki

AU - Yonesaka, Kimio

AU - Yoshimura, Kenichi

AU - Boku, Narikazu

AU - Nosho, Katsuhiko

AU - Takano, Toshimi

AU - Hyodo, Ichinosuke

PY - 2017/5/11

Y1 - 2017/5/11

N2 - Background: Five-weekly S-1 plus cisplatin (SP) therapy is the standard care for advanced gastric or esophagogastric junction cancer (GC/EGJC) in East Asia. However, its efficacy and safety when combined with trastuzumab therapy for human epidermal growth factor receptor 2 (HER2)-positive advanced GC/EGJC remains unclear. Methods: Patients received 5-weekly SP therapy (S-1 at 40–60 mg twice daily for 21 days plus cisplatin at 60 mg/m2 on day 8, every 5 weeks) plus trastuzumab therapy (first dose of 8 mg/kg, then 6 mg/kg every 3 weeks). The primary end point was the response rate, and the secondary end points included progression-free survival, overall survival, safety, and serum biomarker levels. Results: Forty-four patients were enrolled. The response rate, progression-free survival, and overall survival were 61% (95% confidence interval 46–76%), 5.9 months, and 16.5 months respectively. The commonest grade 3 or grade 4 adverse events were neutropenia (30%) and anorexia (25%). A significantly higher response rate (92% vs 43%; P = 0.008) and longer progression-free survival (median 14.5 months vs 4.2 months; P = 0.028) were observed in patients with high (n = 14) compared with low (n = 17) pretreatment serum neuregulin 1 levels. Conclusions: Five-weekly SP therapy combined with trastuzumab therapy showed a good antitumor response and acceptable toxicity in HER2-positive advanced GC/EGJC. Serum neuregulin 1 might be associated with the efficacy of this treatment regimen.

AB - Background: Five-weekly S-1 plus cisplatin (SP) therapy is the standard care for advanced gastric or esophagogastric junction cancer (GC/EGJC) in East Asia. However, its efficacy and safety when combined with trastuzumab therapy for human epidermal growth factor receptor 2 (HER2)-positive advanced GC/EGJC remains unclear. Methods: Patients received 5-weekly SP therapy (S-1 at 40–60 mg twice daily for 21 days plus cisplatin at 60 mg/m2 on day 8, every 5 weeks) plus trastuzumab therapy (first dose of 8 mg/kg, then 6 mg/kg every 3 weeks). The primary end point was the response rate, and the secondary end points included progression-free survival, overall survival, safety, and serum biomarker levels. Results: Forty-four patients were enrolled. The response rate, progression-free survival, and overall survival were 61% (95% confidence interval 46–76%), 5.9 months, and 16.5 months respectively. The commonest grade 3 or grade 4 adverse events were neutropenia (30%) and anorexia (25%). A significantly higher response rate (92% vs 43%; P = 0.008) and longer progression-free survival (median 14.5 months vs 4.2 months; P = 0.028) were observed in patients with high (n = 14) compared with low (n = 17) pretreatment serum neuregulin 1 levels. Conclusions: Five-weekly SP therapy combined with trastuzumab therapy showed a good antitumor response and acceptable toxicity in HER2-positive advanced GC/EGJC. Serum neuregulin 1 might be associated with the efficacy of this treatment regimen.

KW - First-line chemotherapy

KW - Gastric adenocarcinoma

KW - Neuregulin 1

KW - S-1

KW - Trastuzumab

UR - http://www.scopus.com/inward/record.url?scp=85019083751&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85019083751&partnerID=8YFLogxK

U2 - 10.1007/s10120-017-0725-6

DO - 10.1007/s10120-017-0725-6

M3 - Article

SP - 1

EP - 12

JO - Gastric Cancer

JF - Gastric Cancer

SN - 1436-3291

ER -